Skip to content

Study on the Improvement Effects of Vitamin D Combined with Exercise on Type 2 diabetes

Study on the Improvement Effects of Vitamin D Combined with Exercise on Type 2 diabetes

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085631
Enrollment
Unknown
Registered
2024-06-14
Start date
2024-06-24
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

exercise group:No less than 150 minutes of aerobic exercise per week
Vitamin D combined with exercise intervention group:Vitamin D 2400 IU/d and no less than 150 minutes of aerobic exercise per week
control group:placebo
Vitamin D intervention group:Vitamin D 2400 IU/d

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Meet the diagnostic criteria for type 2 diabetes in the Chinese Guide for Prevention and Control of Type 2 Diabetes (2020 Edition), with typical diabetic symptoms and a random blood glucose level of =11.1 mmol/L or a fasting plasma glucose (FPG) level of =7.0 mmol/L; ? Age range of 45-65 years; ? Mainly treated with dietary therapy or drug control.

Exclusion criteria

Exclusion criteria: ? Diagnosed with diabetes only during pregnancy; ? Those who need to use insulin injection for blood glucose control; ? Those who have taken vitamin D supplements, calcium supplements, and omega-3 supplements in the past 3 months; ? Those with hypervitaminosis D, hypercholesterolemia, hypercalcemia (>2.6 mmol/L), hyperphosphatemia with renal osteodystrophy; ? Those with a history of heart disease and cardiac insufficiency; ? Those with other serious diseases, such as osteoporosis, fractures, gastrointestinal dysfunction, renal insufficiency (serum creatinine > 1.5 mg/dL; glomerular filtration rate < 60 mL/min), liver dysfunction, atherosclerosis, cirrhosis, mental illness, collagen disease, cerebrovascular disease, cancer, and other diseases that affect movement; ? Those planning to change hypoglycemic drugs during the trial; ? Those who have already developed complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and diabetic foot; ? Those with a weight change of more than 5% in the past 3 months; ? Those with other diseases that affect blood sugar levels, such as hyperthyroidism; ? Those with regular exercise habits; ? Those allergic to the ingredients in the intervention or placebo; ? Those undergoing weight loss treatment; ? Those who have had sunbathing on the beach, in a swimming pool, or anywhere else in the past 3 months; ? Pregnant or lactating women; ? Those who cannot correctly answer the questionnaire questions or cannot follow the research procedures; ? Those participating in other clinical trials at the same time; ? Those who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
FBG(fasting blood-glucose);HDL;SOD;GR;8-OHdG;ALT;AST;Serum phosphorus ;

Secondary

MeasureTime frame
HbA1c;insulin;CRP;OGTT;25(OH)D;CHO;LDL;

Countries

China

Contacts

Public ContactWei Liu

Peking University Third Hospital

liuwei19560912@163.com+86 188 1133 1956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026